Beyond multidrug-resistant tuberculosis in Europe: A TBNET study

for the TBNET

Research output: Contribution to JournalArticleAcademicpeer-review


© 2015 The Union.The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe.We evaluated secondline drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrugresistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70% to any second-line injectable drug. Respectively >90% and >80% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43%) and XDR-TB patients (49%).
Original languageEnglish
Pages (from-to)1524-1527
JournalInternational journal of tuberculosis and lung disease
Issue number12
Publication statusPublished - 1 Dec 2015
Externally publishedYes


Dive into the research topics of 'Beyond multidrug-resistant tuberculosis in Europe: A TBNET study'. Together they form a unique fingerprint.

Cite this